# CLINICAL UTILITY OF A NEUROBLASTOMA MONOCLONAL ANTIBODY

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 1987 · $190,856

## Abstract

In this research, a recently developed monoclonal antibody, Mab 126,
reactive with a ganglioside antigen, GD2, on neuroblastoma will be
investigated for its potential application to the diagnosis and management
of neuroblastoma.  Preliminary findings showed that the expression of GD2
antigen appears to be restricted to neurectodermal tumors and tissues and
that serum levels of GD2 may serve as a tumor marker for both serological
diagnosis and therapeutic monitoring of neuroblastoma.  We plan to conduct
a prospective, long-term study of patient materials collected from more
than 30 member institutions of the Pediatric Oncology Group.  We will
assess the value of GD2 antigen as detected by Mab 126 in the tissue
diagnosis of neuroblastoma and in clinical staging of neuroblastoma.  We
will test the validity of a serological diagnosis of neuroblastoma and will
correlate the serum levels of GD2 at the time of diagnosis with the
clinical features and final outcome of neuroblastoma patients to determine
their prognostic value.  The serum levels of GD2 will be correlated with
clinical course to assess the usefulness of circulating GD2 as a tumor
marker in monitoring neuroblastoma patients.  We will search for the
presence of circulating antibody to GD2 and their antigen-antibody
complexes in patients with neuroblastoma and determine their clinical
relevance.  We also plan to examine the effects of Mab 126 and antibody
against GD2 found in patients' sera on the growth of culture neuroblastoma
cells and their expression of GD2 antigen.  These undertakings will
delineate the value of Mab 126 in the tissue diagnosis and serological
diagnosis, in clinical staging and prognostication, and in therapeutic
monitoring of neuroblastoma.  It may also provide the first model system in
which the interaction between a well-defined tumor-associated antigen and
its antibody can be dissected.  (2)

## Key facts

- **NIH application ID:** 3179806
- **Project number:** 5R01CA040186-03
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN DIEGO
- **SAM.gov UEI:** UYTTZT6G9DT1
- **Principal Investigator:** Alice L. Yu
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1987
- **Award amount:** $190,856
- **Award type:** 5
- **Project period:** 1985-09-01 → 1988-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3179806

## Citation

> US National Institutes of Health, RePORTER application 3179806, CLINICAL UTILITY OF A NEUROBLASTOMA MONOCLONAL ANTIBODY (5R01CA040186-03). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3179806. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*